Rigel Pharmaceuticals, Inc.  today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles ...

Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.

Meaghan is an editor and writer who also has experience practicing holistic medicine as an acupuncturist and herbalist. She's passionate about helping individuals live full, healthy and happy lives at ...

David Berman, MD, PhD has been appointed as Moderna ’s chief development officer, beginning March 2. The Department of Health and Human Services announced the addition of 21 members to a federal ...

Amgen Inc. said as part of its quarterly results that the company has turned down a request from the U.S. FDA that Tavneos (avacopan) be taken off the market. The complement 5a receptor antagonist was ...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.